This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

3 Antibiotic Stocks Targeting Most Urgent Bacterial Threats

NEW YORK (TheStreet) -- The U.S. Centers for Disease Control and Prevention recently issued a report highlighting antibiotic resistance as a growing public health issue and a catalyst for the development of novel antibiotic compounds. Investing in companies developing new antibiotics has been historically difficult because of the drugs' limited peak sales potential and risks posed by generic competition. But this investment overhang is lifting due to the dearth of new antibiotic agents and the growing threat of antibiotic resistance.

The CDC report and other recent government actions are improving the economics of the antibiotic market, making now the time to invest in high-quality companies focused on particular areas of need.

The U.S. government characterizes three strains of bacteria as urgent threats: Clostridium difficile (C. difficile), Carbapenem-resistant Enterobacteriaceae (CRE) and drug-resistant Neisseria gonorrhoeae. Let's take a look at each of these bacteria in detail and highlight companies currently developing antibiotics against them.

C. difficile: The CDC estimates there are about 250,000 C. difficile infections a year leading to 14,000 deaths and $1 billion in medical costs. From 2000 to 2007 annual deaths increased by 400% due to the development of a strain that was resistant to fluoroquinolone antibiotics.

Cubist Pharmaceuticals (CBST) is best placed to address the C. difficile threat. The company markets Dificid, approved to treat C. difficile, and has a follow-on compound, surotomycin, in phase III studies. Based on phase II study results, the latter has the potential to significantly reduce the risk of C. difficile recurrence and limited the impact on "healthy" bacteria that normally inhabits the bowel.

Carbapenem-resistant Enterobacteriaceae (CRE): While there are only 9,000 infections and 600 deaths a year from this bacteria, this particular strain is feared because almost none of the currently approved antibiotics can treat it effectively. The high level of CRE resistance to current drugs means about 50% of bloodstream infections are fatal. As such, there is a pressing need to find new products that have the capacity to treatment CRE infections.

Tetraphase (TTPH) recently published additional data on eravacycline, a next-generation tetracycline, showing efficacy against multi-drug resistant bacteria, including CRE. Eravacycline phase II data for complicated intra-abdominal infections shows broad activity against gram-positive and negative bacteria, which means the drug has the potential to be a broad spectrum antibiotic addressing the urgent threat of CRE.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs